Table 1. Clinical characteristics of NFC and IPF patients.
| Characteristic | IPF (N=9) | Non Fibrotic (N=8) |
|---|---|---|
| Sex (no. of subjects) | ||
| Male | 8 (90%) | 3 (37.5%) |
| Female | 1 (10%) | 5 (62.5) |
| Age (yr) | ||
| Mean ( ± SEM) | 59.77 ± 3.39 | 69.5 ± 3.3 |
| Range | 40 - 70 | 58 - 80 |
| Length of symptoms (yrs) | ||
| Mean ( ± SEM) | 4.86 ± 1.38 | NA |
| Range | 1 - 11 | NA |
| Smoking (no. with >10 pack/years) | 7 | 5 |
| FEV1 (% predicted ± SEM) | 39.56 ± 3.675 | 112.9 ± 11.04 |
| FVC (% predicted ± SEM) | 45.63 ± 6.074 | 92.54 ± 10.51 |
| DLCO (% predicted ± SEM) | 26.63 ± 3 | ND |
| PA mean (% predicted ± SEM) | 28.38 ± 2.57 | ND |
| Treatments | ||
| Prednisone | 7 | 0 |
| Mycophenolate Mofetil | 5 | 0 |
| Azathioprine | 2 | 0 |
| Methylprednisolone sodium succinate | 2 | 0 |
| Tacrolimus | 2 | 0 |
This table shows the clinical characteristics of the human lung myofibroblasts isolated from both the NFC (n=8) and IPF (n=9) donors. Key; NA – Not applicable, ND- Not done.